AstraZeneca AZN

Pascal brings a passion for science and medicine, significant experience in established and emerging markets, strength of strategic thinking and execution, a successful track record of managing change and executing strategy, and the ability to lead a diverse organisation. He served as COO of Roche’s pharmaceuticals division and, prior to that, as CEO of Genentech. Pascal has worked in senior management roles in several major companies around the world. He is a Doctor of Veterinary Medicine and holds an MBA from HEC Paris. In 2022, Pascal received a knighthood for services to life sciences and leadership in the global response to the COVID-19 pandemic. Other appointments: Pascal is on the Board of Sustainable Markets Initiative Limited. Pascal Soriot, Chief Executive Officer of the Company, has been appointed a director of Agilent Technologies Inc. with effect from 21 May 2025.

Michel was previously Vice-Chairman of UBS Group AG (2010-2019), Chairman of Syngenta and Syngenta Foundation for Sustainable Agriculture (2013-2017) and Chairman of SwissHoldings (2013-2015). Between 2005 and 2013, Michel was CFO of ABB Ltd and interim CEO during 2008. He joined ABB from Baxter International Inc., where he was CFO Europe from 2002-2005. Prior to that, he spent 18 years at The Dow Chemical Company, serving as CFO of Dow’s Global Polyolefins and Elastomers division between 1997-2002. In July 2022, AstraZeneca announced that Michel will succeed Leif Johansson as Non-Executive Chair of the Board at the conclusion of the Company’s AGM in April 2023. Other appointments: Michel is a Non-Executive Director of Vodafone Group plc and Louis Dreyfus Int’l Holding BV, Chairman of IMD Business School.

Philip was previously Group Finance Director of Prudential and Old Mutual. He has served as chairman of the 100 Group of Finance Directors and as a member of the Takeover Panel. He is a Fellow of the Institute of Chartered Accountants in England and Wales. Philip graduated in Philosophy, Politics and Economics from the University of Oxford, where he is a St Edmund Fellow, and holds an MSc in Behavioural Science from LSE. Other appointments: Philip serves as a Non-Executive Director of Legal & General and Non-Executive Director of Lancashire Holdings where he will assume the role of Chair following its 2024 AGM. He is Treasurer of the London Library and Chairman of the Board of Governors of Eastbourne College.

Until February 2018, Sheri was CEO and a Director of Avon Products, Inc. and, prior to that, had a 30-year career at Johnson & Johnson (J&J), latterly serving as Vice-Chairman of the Executive Committee, responsible for the Pharmaceuticals and Consumer business segments. Sheri joined J&J as an R&D scientist and subsequently managed businesses in every major product sector. She holds a BSc in Textile Chemistry from the University of Massachusetts Dartmouth, an MSc in Chemical Engineering from Princeton University and an MBA from Rutgers University. Other appointments: Sheri serves on the boards of Stryker, Kimberly-Clark, and Sail Biomedicines. She is also an industrial adviser for EQT, and in connection serves on the boards of Galderma, Parexel and is Chair of Dechra.

Marcus has international business experience across various industry sectors, including the pharmaceutical industry from his directorship with Astra prior to 1999. Other appointments: Marcus is Chair of Skandinaviska Enskilda Banken AB, Saab AB and FAM AB. He is Vice-Chair of Investor AB and Vice-Chair of EQT AB. Marcus is also Chair of the Royal Swedish Academy of Engineering Sciences and a Board member of the Knut and Alice Wallenberg Foundation

Anna joined London Stock Exchange in 2020 as CFO, ahead of its acquisition of Refinitiv. Prior to this, she was an Executive Director and the CFO of Johnson Matthey Plc and, before that, spent 17 years at Diageo plc in a number of senior finance roles. She brings extensive expertise in accounting, corporate finance and M&A, as well as experience of business diversification, transformation and strategy. Anna was previously a Non-Executive Director of ITV plc and served on its Audit Committee and Remuneration Committee during most of that period. Other appointments: Anna will step down from her role at London Stock Exchange in 2024 to join Nestlé S.A. as CFO and a member of Nestlé’s Executive Board.

ony is the Li Shu Fan Medical Foundation endowed Professor and Chairman of the Department of Clinical Oncology at the Chinese University of Hong Kong. His work includes multiple aspects of lung cancer research, including biomarker and molecular targeted therapy in lung cancer. Tony is the Past President of the International Association for the Study of Lung Cancer and a past Board member of the American Society of Clinical Oncology. He has achieved numerous awards including the European Society for Medical Oncology (ESMO) Lifetime Achievement Award, Giant of Cancer Care, and the Bronze Bauhinia Star. Other appointments: Tony is Non-Executive Director of HUTCHMED (China) Limited, member of the Scientific Advisory Board of Prenetics Global Limited and serves on the board of Insighta.

Birgit Conix will be appointed to the board as non-executive director with effect from 01 February 2025. Birgit joined Sonova and became Chief Financial Officer and a member of the Management Board in 2021. She was previously Chief Financial Officer and member of the Executive Board of TUI, a global leader in tourism, from 2018 to 2021. Before joining TUI, she was Chief Financial Officer of the Belgian media, cable and telecommunications business Telenet Group from 2013 until 2018. Prior to that, she held various senior positions in finance, strategy and business operations in the pharmaceuticals and medical devices business units at Johnson & Johnson, and in finance at Heineken, Tenneco and Reed Elsevier. In addition to her role as CFO of Sonova, Birgit is a member of the Supervisory Board of ASML, one of the world's leading manufacturers of chip-making equipment in the semiconductor industry, where she is Chair of the ESG Committee and a member of the Audit Committee. Birgit holds an MBA from the Booth School of Business, University of Chicago and a Master of Science in Business Economics from the University of Tilburg.

Karen Knudsen will be appointed to the board as non-executive director with effect from 11 April 2025 at AGM. Karen is a globally-recognised cancer scientist and executive leader. She has a track record of translational discoveries in advanced prostate cancer that shaped understanding and treatment approaches, as well as expertise in healthcare innovation, strategic partnerships and organizational growth. Most recently, she served as Chief Executive Officer of the American Cancer Society (ACS) and its advocacy affiliate, ACS Cancer Action Network, where she led the organization through a period of transformative growth, increasing revenue and expanding research, advocacy and patient support.Karen previously served as Hilary Koprowski Endowed Professor and Chair of Cancer Biology at Thomas Jefferson University and Enterprise Director of the Sidney Kimmel Comprehensive Cancer Center, a National Cancer Institute (NCI)-designated centre of excellence. Karen has held various leadership roles in oncology, including EVP of Oncology Services at Jefferson Health and serving on the NCI Board of Scientific Advisors, as President of the Association of American Cancer Institutes, and on the Board of Directors of the American Association for Cancer Research. Her contributions to oncology and healthcare leadership have been recognized with numerous awards, including honours from the Endocrine Society, the Prostate Cancer Foundation and the American Society for Clinical Oncology. Karen is Professor Emerita of Thomas Jefferson University and the Sidney Kimmel Comprehensive Cancer Center. She is an Independent Director of Exai Bio, serves on the board of Research!America, and as a board adviser for ArteraAI.

Wan Ling Martello has been appointed as Non-Executive Director with effect from 1 September 2026. Wan Ling Martello is a founding partner of BayPine, Independent Director of the Alibaba Group and Director of The Lovesac Company. Wan Ling Martello has spent most of her career leading executive teams and organisations in the consumer products and retail industries, and has significant expertise in B2C technology-enabled business models and digital transformation. She has held senior leadership roles at Nestlé, Walmart, NCH Marketing Services (a former subsidiary of Nielsen), Borden Foods and Kraft Foods. Among her career highlights, Wan Ling served as Nestlé SA's global CFO, where she revitalised the global finance organisation, established a new data-driven resource allocation and portfolio management framework for the entire company, and led numerous M&A transactions. She was then appointed as CEO of Nestlé's Asia, Oceania and Sub-Saharan Africa (AOA) business and re-focused the entire business on driving growth and using digital transformation initiatives to drive greater consumer engagement. Wan Ling is a founding partner of BayPine, a private equity firm based in Boston, USA. In addition to her role at BayPine, Wan Ling is an Independent Director of Alibaba Group, listed on the New York Stock Exchange and a Director of The Lovesac Company, listed on Nasdaq. From June 2017 to May 2025, Wan Ling was a director of Uber Technologies, Inc. (listed on the New York Stock Exchange from May 2019), and from January 2021 to April 2025, Wan Ling was an independent non-executive director of Stellantis N.V. (listed on the New York Stock Exchange, Euronext Milan and Euronext Paris). Wan Ling holds a BS from the University of the Philippines and an MBA-MIS from the University of Minnesota.

Matthew Shaun Bowden, Company Secretary